Lysodren (Mitotane) 500mg 100 Tablets | HRA Pharma EU Original | GLT

Generic Information: Lysodren (Mitotane) — European Union Version

The European Union presentation of Lysodren is the same originator mitotane 500 mg scored tablet that the rest of the world uses, marketed through the HRA Pharma Rare Diseases network that has held the European rights for over fifteen years. The EU's relationship with the drug is formalized through orphan designation granted by the European Medicines Agency, recognizing ACC as precisely the kind of ultra-rare, life-threatening condition orphan-drug rules exist to serve. GLT supplies the EU presentation in bottles of 100 tablets, with European labeling and batch traceability that hospitals across the region recognize.

What Is Lysodren (Mitotane) Used For?

The European indication is the same as the global label: treatment of inoperable, functional or nonfunctional adrenocortical carcinoma. Across Europe, mitotane sits at the center of ACC management in every major reference center — used as first-line systemic therapy for advanced disease, as adjuvant treatment after surgery to push recurrence further out, and, in functional tumors, to suppress the cortisol excess that produces Cushing's syndrome. Its off-label role in controlling severe hypercortisolism, including in Cushing's syndrome independent of ACC, is also well established in European practice.

How Does Lysodren (Mitotane) Work?

Mitotane's mechanism is singular in oncology: it is a direct adrenal cytotoxic. By altering mitochondrial function and inhibiting SOAT1 it destroys adrenocortical cells, while independently suppressing the adrenal's steroid synthesis. The practical result is that the drug both attacks the tumor and shuts off the hormone overproduction that makes functional ACC so dangerous. Because it is highly lipophilic, it accumulates in fat tissue and clears from the body over weeks to months, which is the single most important pharmacokinetic fact a prescribing physician manages.

Indications of Lysodren (EU)

The EU label covers inoperable functional or nonfunctional adrenocortical carcinoma, with the EMA's orphan designation underlining the disease's rarity and the absence of alternatives. European centers also use mitotane in the adjuvant setting after complete resection in high-risk patients and off-label for Cushing's syndrome, guided by the same monitoring principles the label requires: blood counts, liver tests, lipid and thyroid function, and plasma-level tracking toward the 14–20 mg/L target.

Dosage and Administration

Initial dosing is 2–6 g per day in three or four divided doses with food, escalated against measured plasma levels into the 14–20 mg/L therapeutic range. The rule of thumb European teams follow: levels above 20 mg/L mark the threshold where neurological toxicity becomes likely, triggering dose reduction by half or more. Once the target is reached — often three to five months in — the dose is usually maintained, with levels checked monthly and again for months after stopping, given the drug's extreme half-life of 18 to 159 days. In overweight patients or after significant weight loss, levels shift as fat stores change and must be re-checked.

Side Effects of Lysodren

The European experience mirrors the global profile. Gastrointestinal effects — anorexia, nausea, vomiting, diarrhea — and central nervous system depression — lethargy, dizziness, vertigo, depression — are the most frequent, the neurological ones appearing in roughly 40% of patients. Adrenal insufficiency is expected in many patients and managed with steroid replacement; hepatotoxicity, hematologic changes and prolonged bleeding time are monitored; and the boxed warning about adrenal crisis during shock, trauma or infection applies everywhere. Mitotane's strong CYP3A4 induction means a careful interaction review, and its fetal toxicity means effective nonhormonal contraception during and after treatment.

Storage Instructions

Store in the original bottle, tightly closed, at room temperature away from light and moisture. No refrigeration. As a cytotoxic agent, unused tablets should go to a pharmacy take-back point, not household waste.

Why Choose Lysodren (EU) from GLT?

European buyers and those who prefer EU-origin regulated stock choose this presentation for its EMA-backed lineage and batch traceability; buyers elsewhere often select it as a cost-balanced alternative between the US original and the Lao generics. GLT ships sealed EU cartons with documentation and photographs on request, serves individuals and institutions, and answers every message personally on WhatsApp +86 15234153837 or [email protected]. Tell us your monthly requirement and we will quote the EU, US, China and Lao options together so you can compare landed cost honestly.

How to Order Lysodren (Mitotane)

Contact GLT on WhatsApp +86 15234153837 or at [email protected] with your quantity. You will receive a formal quotation with courier and payment options, typically within one working day, and sealed stock is dispatched with full export documentation after confirmation. Standing supply arrangements keep treatment uninterrupted.

FAQ

Is the EU Lysodren different from the US one? Same originator 500 mg tablet and same molecule; the difference is European packaging, the EMA orphan designation and the marketing route — not the medicine.

What is orphan designation? A status the EMA and other regulators grant to drugs for very rare diseases, offering incentives to keep them available — mitotane received it for ACC.

How often are blood levels checked? Every two weeks during titration, then monthly once stable, and for weeks or months after stopping because the drug clears very slowly from fat tissue.

Does the EU version cover Cushing's syndrome? The formal indication is ACC, but mitotane's steroid-suppressing action is used off-label for severe Cushing's syndrome across Europe.

Can GLT supply the Lao generics as an alternative? Yes — MITODX, LuciMito and Mytanne are listed on our site and quoted alongside the originals.